Research on effectiveness of behavioral activation therapy for Japanese cancer patients with depression - Research on effectiveness of behavioral activation therapy for Japanese cancer patients with depression

Department of Psycho-Oncology, National Cancer Center Hospital, Japan0 个研究点目标入组 32 人开始时间: 2019年3月6日最近更新: 2023年11月20日

适应症

试验速览

阶段: 未知
状态: 已完成
发起方
入组人数: 32

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

The completion rate was 75% (24/32), which was similar to previous studies. The total HAMD17 score significantly improved after the program. The remission rate of depression was 62.5% (20/32), which was above the defined threshold value (30%). All but two secondary outcomes significantly improved after the program (p??<??0.05). The feasibility and preliminary effectiveness of BA for patients with cancer and depression in Japan were suggested.

研究设计

研究类型: Interventional

入排标准

年龄范围: 20years-old 至 65years-old（—）
性别: All

入选标准

未提供

排除标准

•they show either serious physical or mental symptoms (cognitive functional disorders,disturbance of consciousness, depressive conditions accompanied with psychiatric symptoms, imminent suicidal ideation, and/or record of contemplation of suicide) they have experienced intervention by experts in the past such as behavioral activation therapy the physicians in charge judge it difficult for their patients to participate in the program

研究者

发起方

Department of Psycho-Oncology, National Cancer Center Hospital, Japan

相似试验

已完成

2 期

Evaluation of the Usefulness of Pre-operative Exemestane (EXE) Therapy for Treatment of Hormone-Sensitive Breast Cancer in Postmenopausal Patients, and EXE + TC Combination Therapy for Nonresponders to EXE Therapy. (JBCRG-11TC)ER positive, HER2 negative, Stage II or IIIA [T2-3,N0-2,M0], Primary Postmenopausal Invasive Breast Cancer Patients

JPRN-UMIN000004752Japan Breast Cancer Research Group (JBCRG)58

招募中

2 期

Study on effectiveness of behavioral activation therapy program for depression in advanced cancer patientsdepressive symptoms

JPRN-jRCT1030210687Hirayama Takatoshi38

已完成

不适用

Phase ? Study to Evaluate the Efficacy and Safety of Regdanvimab for Patients with Mild to Moderate Symptoms of Severe Acute Respiratory Syndrome Coronavirus 2 Infectio

KCT0006254Incheon Medical Center19

进行中（未招募）

2 期

A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical CystectomyUrinary Bladder Neoplasms

NCT04640623Janssen Research & Development, LLC220

已完成

不适用

Effectiveness of add-on group behavioral activation treatment for depression in psychiatric care

ISRCTN10647845niversity of Helsinki and Helsinki University Hospital140